Bernstein analyst Lee Hambright raised the firm’s price target on Boston Scientific (BSX) to $100 from $92 and keeps an Outperform rating on the shares. Keeping up the trend from Q1 and Q2, Boston Scientific delivered another clean beat-and-raise quarter as top-line grew 18% organic and landed 4% ahead of Street estimates on strength across segments, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $98 from $87 at Wells Fargo
- Boston Scientific price target raised to $98 from $92 at Citi
- Boston Scientific (NYSE:BSX) Q3 Earnings Show Significant Sales Growth
- Boston Scientific weakness a buying opportunity, says Stifel
- Boston Scientific price target raised to $97 from $93 at BTIG